

27 July 2026

ASX Announcement

June 2026 Quarterly Activity Report

Firebrick Pharma Limited (ASX:FRE) (**Firebrick, Company**) is pleased to provide its business activity update for the quarter ending 30 June 2026, along with its Appendix 4C quarterly cash flow report.

REVIEW OF QUARTERLY OPERATIONS

Operations

During the quarter, the Company announced another two granted patents. On 13 May, the Company announced that its pandemic use patent titled "Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes" had been accepted in Canada. This patent, which expires in 2040, has also been accepted and/or granted in the US, Europe, Australia, and the Philippines, and is pending in other countries

On 3 June, the Company announced that its patent titled: "Improved Virucidal Formulations" had been granted in New Zealand. This patent, which expires in 2041, has also been granted in Australia and South Africa, and is pending in other international markets.

Financial Overview

Cash used in Operations

Cash operating expenses in the June quarter were \$839k, which was up 2% on the March quarter cash expenses (\$821k). June quarter expenses were higher than expected due to several pre-payments for project costs for the coming September 2026 quarter, and some other one-off payments that are not expected to be repeated in future quarters. Overall, the annual expenses for FY26 were \$3,078k, which was on a par with the previous year (\$3,068k).

The cash expenses for the quarter were offset by sales receipts of \$66k (as reported below) and other miscellaneous receipts, bringing net cash 'burn' for the quarter to \$768k. Overall cash burn for the FY26 year was \$2,603k, representing an average of \$650k per quarter. Cash at the end of June 2026 was \$1,322k.

As per item 6 of the Appendix 4C report for the quarter, payments to related parties and their associates were \$320k, comprising executive salaries and non-executive director fees.

Sales Development

Sales receipts for the June quarter were \$66k, bringing annual cash sales for FY26 to \$227k. This compares with reported FY25 cash sales of \$305k. However, adjusting for the one-off 'pipeline' receipt of \$146k in June 2025 (refer announcement 23 July 2025), the FY25 sales figure would be \$159k, indicating sales growth of 43% in FY26.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman of Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick Pharma is developing and commercialising novel formulations and uses of povidone-iodine (PVP-I). Its first product, Nasodine[®] Nasal Spray (0.5% PVP-I), has been introduced into the United States, Singapore, and Fiji. Nasodine Nasal Spray was also recently approved for marketing in Indonesia, and the Company is pursuing approval in the Philippines and other markets. Nasodine[®] Throat Spray is the first follow-on product in the Nasodine range and is now available in Singapore and Fiji. Firebrick recently announced plans for a total of up to four products in the Nasodine range and expansion of sales to up to 10 markets over three years. For further information, visit **firebrickpharma.com**

Contacts:

Media contact:

Matthew Wright, NWR Communications
matt@nwrcommunications.com.au

Shareholder Company contact:

Kam Watson, Firebrick Pharma
investors@firebrickpharma.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

FIREBRICK PHARMA LIMITED

ABN

64 157 765 896

Quarter ended ("current quarter")

30 JUNE 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	66	227
1.2 Payments for		
(a) research and development	(142)	(419)
(b) product manufacturing and operating costs	(39)	(362)
(c) advertising and marketing	(123)	(442)
(d) leased assets (including premises)	(21)	(84)
(e) staff costs	(348)	(1,063)
(f) administration and corporate costs	(166)	(709)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	4	9
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives – 2025 R&D Tax Incentive	-	251
1.8 Other (GST payments)	1	(11)
1.9 Net cash from / (used in) operating activities	(768)	(2,603)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	-	-
(d) investments	-	-
(e) intellectual property	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	-	-

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	1,405	3,052
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	4	16
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(110)	(126)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	1,299	2,942

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	791	983
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(768)	(2,603)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	1,299	2,942
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of period	1,322	1,322

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,322	791
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,322	791

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	320
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
N/A		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(768)
8.2 Cash and cash equivalents at quarter end (item 4.6)	1,322
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	1,322
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	1.7
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
No. The Company expects net operating cash flows for the coming quarter to be reduced compared with the June quarter result.	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
The Company successfully raised \$1.5M via a Placement in April 2026. The Company has the current capacity to raise additional funds if needed and management has assessed other forms of available funding and is confident that based on its past successes it will be able to secure funds if required.	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Yes. Refer to 8.6.1 and 8.6.2.	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 July 2026

Authorised by: By the Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.